SLC5A2 and kidney failure: We foresee that the guidelines for the management of IgAN will incorporate in the future the use of SGLT2 inhibitors and endothelin receptor antagonists, such as sparsentan, as options for the optimized supportive care approach and the inclusion of TRF-budesonide therapy for patients with high risk of progressive disease.58,80,95 It is also important to keep in mind that patients with IgAN with proteinuria levels <1 g/day remain at risk of kidney failure.